


Searching News Database: CDAD
HSMN NewsFeed - 18 Jun 2020
Almirall Announces FDA Approval Of Updated Label For Seysara(R) (Sarecycline) Tablets
Almirall Announces FDA Approval Of Updated Label For Seysara(R) (Sarecycline) Tablets
HSMN NewsFeed - 18 Mar 2019
Allergan Announces FDA Approval of AVYCAZ(R) (ceftazidime and avibactam) for Pediatric Patients
Allergan Announces FDA Approval of AVYCAZ(R) (ceftazidime and avibactam) for Pediatric Patients
HSMN NewsFeed - 31 May 2016
Allergan Receives FDA Approval of TEFLARO(R) (ceftaroline fosamil) for Pediatric Patients
Allergan Receives FDA Approval of TEFLARO(R) (ceftaroline fosamil) for Pediatric Patients
HSMN NewsFeed - 16 Feb 2016
FDA Accepts Supplemental New Drug Application (sNDA) for TEFLARO(R) (ceftaroline fosamil)
FDA Accepts Supplemental New Drug Application (sNDA) for TEFLARO(R) (ceftaroline fosamil)
HSMN NewsFeed - 21 Jan 2016
Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for DALVANCE(R) (dalbavancin)
Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for DALVANCE(R) (dalbavancin)
HSMN NewsFeed - 19 Aug 2014
Dermira Completes $51 Million Financing and Expands Management Team and Board of Directors
Dermira Completes $51 Million Financing and Expands Management Team and Board of Directors
HSMN NewsFeed - 28 Feb 2013
FDA Grants QIDP and Fast Track Designations for Cubist’s Late-Stage Antibiotic Candidates
FDA Grants QIDP and Fast Track Designations for Cubist’s Late-Stage Antibiotic Candidates
HSMN NewsFeed - 24 Jul 2012
Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
HSMN NewsFeed - 1 Dec 2010
Cubist Pharmaceuticals Receives FDA Approval for 2-Minute IV Injection of CUBICIN
Cubist Pharmaceuticals Receives FDA Approval for 2-Minute IV Injection of CUBICIN
HSMN NewsFeed - 24 Mar 2010
FDA Approves XIFAXAN(R) 550 MG Tablets for Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence
FDA Approves XIFAXAN(R) 550 MG Tablets for Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence
HSMN NewsFeed - 16 Dec 2009
Nanotherapeutics Acquires Two Late Stage Clinical Programs for Alzheimer's Treatment and CDA Disease
Nanotherapeutics Acquires Two Late Stage Clinical Programs for Alzheimer's Treatment and CDA Disease
HSMN NewsFeed - 27 Nov 2009
Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
HSMN NewsFeed - 10 Nov 2009
Ismail Kola joins UCB as Executive Vice President, UCB & President of UCB New Medicines(TM)
Ismail Kola joins UCB as Executive Vice President, UCB & President of UCB New Medicines(TM)
HSMN NewsFeed - 5 Nov 2009
Theravance and Astellas Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States
Theravance and Astellas Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States
HSMN NewsFeed - 30 Mar 2009
Inverness Medical Innovations Launches New FDA Cleared C. DIFF QUIK CHEK COMPLETE(TM) Rapid Test
Inverness Medical Innovations Launches New FDA Cleared C. DIFF QUIK CHEK COMPLETE(TM) Rapid Test
HSMN NewsFeed - 2 Dec 2008
Cubist Names Santosh J. Vetticaden as SVP, Clinical Development and Chief Medical Officer
Cubist Names Santosh J. Vetticaden as SVP, Clinical Development and Chief Medical Officer
HSMN NewsFeed - 10 Nov 2008
Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market
Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market
HSMN NewsFeed - 30 Jul 2008
Oscient Pharmaceuticals Promotes Mark A. Glickman to Senior Vice President, Sales and Marketing
Oscient Pharmaceuticals Promotes Mark A. Glickman to Senior Vice President, Sales and Marketing
HSMN NewsFeed - 2 Jul 2008
Cubist Pharmaceuticals to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V.
Cubist Pharmaceuticals to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V.
HSMN NewsFeed - 24 Jan 2008
FDA Approves MiddleBrook's Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
FDA Approves MiddleBrook's Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
HSMN NewsFeed - 16 Oct 2007
Cubist Pharmaceuticals Announces Exclusive Option to Acquire Illumigen Biosciences
Cubist Pharmaceuticals Announces Exclusive Option to Acquire Illumigen Biosciences
HSMN NewsFeed - 6 Sep 2007
Cubist Pharmaceuticals' CUBICIN Approved for Additional Indications in the EU
Cubist Pharmaceuticals' CUBICIN Approved for Additional Indications in the EU
HSMN NewsFeed - 28 Aug 2007
Cubist Pharmaceuticals Creates COO Position, Adds Scientific Advisory Board
Cubist Pharmaceuticals Creates COO Position, Adds Scientific Advisory Board
HSMN NewsFeed - 1 May 2007
Robert G. Pietrusko Joins ViroPharma as Vice President of Global Regulatory Affairs and Quality
Robert G. Pietrusko Joins ViroPharma as Vice President of Global Regulatory Affairs and Quality
HSMN NewsFeed - 9 Apr 2007
PDL BioPharma Announces Election of L. Patrick Gage as Chairman of the Board
PDL BioPharma Announces Election of L. Patrick Gage as Chairman of the Board
HSMN NewsFeed - 22 Feb 2007
New Treatment Guidelines for Community-Acquired Pneumonia Highlight Utility of FACTIVE Tablets
New Treatment Guidelines for Community-Acquired Pneumonia Highlight Utility of FACTIVE Tablets
HSMN NewsFeed - 12 Feb 2007
sanofi-aventis Announces Update to U.S. Prescribing Information for Ketek(R) (Telithromycin)
sanofi-aventis Announces Update to U.S. Prescribing Information for Ketek(R) (Telithromycin)
HSMN NewsFeed - 26 Jan 2007
Oscient Pharmaceuticals Completes Enrollment in Phase IV Trial of FACTIVE Tablets
Oscient Pharmaceuticals Completes Enrollment in Phase IV Trial of FACTIVE Tablets
HSMN NewsFeed - 22 Jan 2007
Cytokinetics Announces Changes to its Executive Management Team and Board of Directors
Cytokinetics Announces Changes to its Executive Management Team and Board of Directors
HSMN NewsFeed - 29 Dec 2006
Oscient Pharmaceuticals Amends FACTIVE License Agreement with LG Life Sciences
Oscient Pharmaceuticals Amends FACTIVE License Agreement with LG Life Sciences
HSMN NewsFeed - 5 Oct 2006
Oscient Pharmaceuticals and Pfizer, S.A. de C.V. Announce Launch of FACTIVE(R) Tablets in Mexico
Oscient Pharmaceuticals and Pfizer, S.A. de C.V. Announce Launch of FACTIVE(R) Tablets in Mexico
HSMN NewsFeed - 28 Sep 2006
United States Seeing Greater Increases in Clostridium Difficile-Associated Disease Case-Load and Severity
United States Seeing Greater Increases in Clostridium Difficile-Associated Disease Case-Load and Severity
HSMN NewsFeed - 22 May 2006
Oscient Pharmaceuticals Hires Philippe M. Maitre as Senior Vice President and Chief Financial Officer
Oscient Pharmaceuticals Hires Philippe M. Maitre as Senior Vice President and Chief Financial Officer
Additional items found! 43
Members Archive contains
43 additional stories matching:
CDAD
(Password required)
CDAD
(Password required)
